Edeniq has developed patented innovations that unlock cellulosic and starch sugars through a combination of mechanical and biological processes. Edeniq’s capital light and operationally efficient solutions can be easily integrated into existing corn ethanol plants.

Edeniq, a private company founded in 2008, has raised approximately $100 million from some of the world’s leading venture capital firms, including Kleiner Perkins Caulfield & Byers, Draper Fisher Jurvetson, Angeleno Group, The Westly Group, I2BF Global Ventures, and other leading investors, as well as US Department of Energy (DOE) grant funding.

Edeniq’s patented technology is commercially proven, with 29 of the company’s Cellunators installed in 6 US ethanol plants. Edeniq has also signed several license agreements for its Pathway technology, which integrates the mechanical Cellunator equipment with cellulase enzymes to convert corn kernel fiber to cellulosic ethanol.

In 2015, Edeniq generated approximately $20 million in revenue and $6 million in positive EBITDA.

Under the terms of the agreement, Aemetis expects to issue between one and two million shares of its common stock (depending on whether Edeniq stockholders elect to receive part of their consideration in cash or stock) plus cash to be paid over the next 5 years in an amount of up to $20 million (up to $18 million if Edeniq stockholders elect all stock consideration) in exchange for all of the issued and outstanding shares of Edeniq.

Upon completion of the transaction, Edeniq will operate as a wholly-owned subsidiary of Aemetis. The closing of the transaction is expected to occur during the second quarter, and is subject to customary closing conditions and approvals, including the approval of Edeniq's shareholders and the closing of financing by Aemetis to refinance certain liabilities of Edeniq that exist prior to closing.

Headquartered in Cupertino, California, Aemetis owns and operates a 60-million gallon per year ethanol and 420,000-ton animal feed plant in California. Aemetis also owns and operates a 50-million gallon capacity renewable chemicals and advanced fuels production facility on the East Coast of India producing high quality, distilled biodiesel and refined glycerin for customers in Europe and Asia.

Aemetis operates a research and development laboratory at the Maryland Biotech Center, and holds nine granted patents on its Z-microbe and related technology for the production of renewable fuels and biochemicals.